N.J.'s big-bucks experiment
By North Jersey Media Group,
North Jersey Media Group
| 06. 19. 2005
With little fanfare and no direct approval of the electorate, the state of New Jersey has spent hundreds of millions of dollars supporting the biotech industry.
Powerful forces are hard at work in Trenton, selling biotechnology as a way to simultaneously bolster the state economy and improve the health of citizens. Acting Governor Codey has been front and center, promoting a plan to spend $380 million more on research into embryonic stem cells.
Much is at stake in a state where 200,000 jobs depend on the pharmaceutical industry and its ability to develop the next generation of miracle medicines.
But New Jersey's partnership with biotech is already running into problems. It is cloaked in secrecy and riddled with the potential for conflicts. Its goals are at times nebulous.
A thorough review of the effort by The Record found:
Millions of your tax dollars have gone to companies that take valuable research, profits and jobs from New Jersey and strengthen the biotech industry elsewhere.
Millions are being spent on tax breaks and other public subsidies for small biotechs and big pharmaceutical...
Related Articles
By Staff, National Women's Law Center | 08.13.2025
INTRODUCTION
Baby bonuses. Motherhood medals. Fertility tracking. You may have heard of these policy proposals as solutions from the Trump administration to help encourage women to have more children.
Besides falling short of ensuring that people have what they need...
By Zusha Elinson, The Wall Street Journal | 08.12.2025
BERKELEY, Calif.—Tsvi Benson-Tilsen, a mathematician, spent seven years researching how to keep an advanced form of artificial intelligence from destroying humanity before he concluded that stopping it wasn’t possible—at least anytime soon.
Now, he’s turned his considerable brainpower to promoting...
By Cade Metz, The New York Times | 08.04.2025
Image by Mike MacKenzie / CC BY 2.0
In downtown Berkeley, an old hotel has become a temple to the pursuit of artificial intelligence and the future of humanity. Its name is Lighthaven.
Covering much of a city block, this...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...